GlassScriptPhysician profile
Chris J Smith
NPI 1629427083
$1,208.38
in general payments reported to CMS, 2019-2025
27 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $237 · 2023: $373 · 2024: $377 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.57 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $125.60 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $107.73 | 2022-2025 | |
| Daiichi Sankyo INC. | $97.52 | 2023-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $90.43 | 2022-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.37 | 2023 | Xifaxan |
| Exact Sciences Corporation | $52.07 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $50.25 | 2022-2024 | Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $43.39 | 2022 | |
| Abbvie INC. | $43.25 | 2023-2024 | |
| Dexcom, INC. | $41.20 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $33.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $31.77 | 2024-2025 | Voquezna |
| Recor Medical INC | $25.85 | 2024 | Paradise Renal Denervation System |
| Novartis Pharmaceuticals Corporation | $20.61 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $19.92 | 2023 | Tlando, Xyosted, Nocdurna |
| Halozyme INC | $19.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.89 | 2024 | Jardiance |
| Abbott Laboratories | $16.88 | 2024 | Proclaim |
| Corcept Therapeutics | $16.17 | 2025 | Korlym |
| Corium, LLC | $15.70 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $14.36 | 2023 | Rexulti |
| Novo Nordisk INC | $13.95 | 2025 | Rybelsus, Ozempic |
| Cranial Technologies, INC | $13.78 | 2023 | Doc Band |
| Biohaven Pharmaceutical Holding Company LTD. | $13.19 | 2022 | |
| Pfizer INC. | $12.86 | 2023 | |
| Organon LLC | $7.04 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.